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Abstract A well-characterised experimental system, the myo-
genin gene in C2C12 muscle cell culture, was chosen to better
understand the methylation mechanism underlying the regulation
of gene expression. We already demonstrated that demethylation
dynamics of a specific CpG site in the 5P-flanking region of
myogenin well correlates with gene expression and terminal
differentiation. Here we demonstrate that S-adenosylmethionine-
sulphate-p-toluenesulphonate (SAM) inhibits myogenin expres-
sion and myoblast differentiation by delaying the demethylation
of specific CpG in differentiating myoblasts. These results
suggest new perspectives in methylation mechanisms and the use
of SAM in the partial silencing of gene expression, as it could be
required in disease treatment. ß 2001 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
The di¡erentiation of muscle cells is a widely used system to
study the regulation of gene expression. Most of the myogenic
transcription factors are known and in particular the interac-
tion between the basic helix^loop^helix (bHLH) myogenic
factors, like myogenin [1] or MyoD [2], and the HLH repres-
sion factors like the Id [3] family, are known.
Many studies have demonstrated that DNA methylation
plays a central role in the regulation of gene expression [4^
6] but the exact molecular mechanism acting in this modula-
tion is still not well understood [7]; in particular, little is
known about the methylation of myogenic factors. The stud-
ies on methyl binding proteins [8], demethylase activity [9],
and interaction of the methylation machinery with histone
acetylation, established a connection between gene expression,
CpG methylation and chromatin structure [10]. Besides regu-
lating the expression of housekeeping and tissue-speci¢c genes
[11^13], methylation has also been shown to be involved in
tumourigenesis [14^16], and senescence [17].
The involvement of the DNA methylation process with the
regulation of gene expression in muscle di¡erentiation has
been demonstrated using 3-deazaadenosine, which blocks the
S-adenosylmethionine (SAM) metabolic pathway inducing hy-
pomethylation and promotes muscle di¡erentiation [18,19].
Recently we demonstrated the tight correlation between the
demethylation dynamics of a speci¢c CpG site in the 5P-£ank-
ing region of myogenin, its expression and myoblast di¡eren-
tiation [20].
The possibility of silencing the genes regulated by DNA
methylation, through the administration of exogenous SAM,
could open a new pathway in the treatment of pathologies
characterised by gene overexpression. Administering SAM
to C2C12 cells under di¡erentiating conditions, we found
that myoblast di¡erentiation was repressed without a¡ecting
cell growth; the repression is coherent with the inhibition of
myogenin expression, although Id3 expression is not a¡ected.
Finally the methylation of the 5P-£anking region was also
studied with a HpaII/polymerase chain reaction (PCR) multi-
plex assay. We showed that the demethylation dynamics of
myogenin was delayed in cells exposed to SAM. For the ¢rst
time it was possible to observe the direct silencing of a gene by
administrating the methyl donor to the cells. The SAM uptake
into cells, which was indicated as controversial [21], has been
veri¢ed through a high performance liquid chromatography
(HPLC) analysis [22].
2. Materials and methods
2.1. Chemicals
Restriction enzymes and oligo-d(T)16 were purchased from Boehr-
inger Mannheim (Mannheim, Germany). M-MuLV (Moloney murine
leukaemia virus) reverse transcriptase (cloned), Super Taq (Thermus
thermophilus DNA polymerase, licensed Ho¡mann-La Roche), human
placental ribonuclease inhibitor, bu¡er for reverse transcription, bu¡-
er for PCR and xX/HaeIII marker were obtained from HT Biotech-
nology (Cambridge, UK). Oligonucleotides used as primers were syn-
thesised by M-Medical Genenco (Firenze, Italy). All other chemicals
were from Sigma (St. Louis, MO, USA).
2.2. Cell culture
The C2C12 mouse muscle cell line [23] was cultured in F14 medium
supplemented with 50 Wg/ml neomycin and 10% foetal calf serum
(growth medium, GM), or with 1% foetal calf serum (di¡erentiation
medium, DM) which induces di¡erentiation with the appearance of
myotubes and of creatine kinase (CK) activity, as previously described
[24]. Flasks were coated with 0.2% gelatin to favour di¡erentiation.
24 h after plating, cells were either shifted to DM, or reefed with GM
according to the experimental design. SAM was added to DM accord-
ing to the experimental design. Cultures were reefed every second day
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with the appropriate medium. The times indicated refer to medium
shift (or change) as day 0.
2.3. Di¡erentiation assay
Cells to be used for enzymatic test, either in GM or DM, were
rinsed twice with phosphate bu¡ered saline (PBS) and frozen at
380‡C until used. The frozen cells were scraped into 1 ml of 50
mM Tris^HCl (pH 7.2) and 1 mM dithiothreitol, soni¢ed for 15 s
in ice and centrifuged. Supernatant was used for CK (EC 2.7.3.2) and
total protein content assay [25]. The results were expressed as the
average of at least three experiments in mU CK/Wg proteins þ S.E.M.
2.4. HPLC analysis
Cell cultures were rinsed twice with PBS and frozen at 380‡C.
After thawing, cells were scraped into 1 ml of deionised water and
soni¢ed for 15 s in ice. The macromolecules were precipitated using
1.5 M PCA solution at 4‡C for 1 h adjusting the pH to 4^5 with KOH
and then centrifuged for 15 min at 9000Ug. The supernatant was
freeze-dried and later subjected to HPLC analysis [26]. The HPLC
measurements were carried out using a Varian HPLC system (Varian,
Walnut Creek, CA, USA) equipped with a ProStar 210 pump and a
UV detector (ProStar 320) set to 254 nm.
Remote control of the HPLC system, data acquisition and calcu-
lation of peak areas were performed via computer-based data system
(Varian Star 5.3). The samples were injected through an injection
valve with a 20 Wl sample loop. The mobile phase was pumped at a
£ow-rate of 1.00 ml/min. The samples were dissolved in water and
injected onto the reverse-phase column (Alltima, C18-LL 100A 5u,
length 150 mm, i.d. 4.6 mm).
The mobile phases were (A) 10 mM ammonium formate and (B)
acetonitrile (HPLC grade, Aldrich). A 20 min gradient from 0^10% B
followed by 90% A and 10% B for 20 min was applied.
Standard samples of SAM, SAH dissolved in water were run before
and after the experimental samples.
2.5. RNA extraction and expression assay
Total RNA extraction was performed by the acidi¢ed phenol pro-
cedure [27,28]. For the expression studies by reverse transcription
(RT)-PCR, we performed a reverse transcription with 1 Wg of total
RNA, using 50 pmol of oligo-d(T)16 per sample, with 50 U per sample
of M-MuLV reverse transcriptase at 42‡C for 1 h, followed by heat
inactivation at 94‡C for 5 min. The total reaction volume was 20 Wl
per sample in the assay bu¡er as indicated by the manufacturer. The
subsequent ampli¢cation reactions were carried out as previously de-
scribed [20] for mouse myogenin (GenBank, accession number
M95800), and for mouse Q-actin (GenBank, accession number
L21996) cDNAs. For the ampli¢cation of Id3 (GenBank, accession
number M60523) cDNA we used MMID3P5 (5P-CTACTCTCCA-
CATGAAGGCGCTGAGCC-3P, nucleotides (nt) 46^73) as forward
primer and MMID3M1 (5P-TTTCTCCAAGGAAACCAGAAGAA-
CAGC-3P, nt 784^810) as backward primer, obtaining an ampli¢ed
fragment of 765 bp. The use of Q-actin as internal standard acted as
control for the processing of equal quantity samples.
2.6. DNA extraction and methylation assay by multiplex HpaII/PCR
Genomic DNA was extracted using a standard phenol/chloroform
method followed by ethanol precipitation [28]. Genomic DNA was
treated separately with the following restriction endonucleases:
(i) EcoRI, which has no recognition sites internal to the ampli¢ed
fragments of myogenin gene; (ii) HpaII, which has a recognition site
internal to the 5P-£anking region and three recognition sites internal
to exon 1, and is methylation-sensitive (i.e. it fails to cut if the CCGG
recognition sequence is methylated at any C). Exon 3, which possesses
no HpaII or EcoRI recognition sites, was used as internal standard. In
each case, 1.5 Wg of genomic DNA were digested overnight at 37‡C
with 5 U of enzyme, and then with 3 U more for an additional 6 h, in
a ¢nal volume of 40 Wl of the bu¡er provided by the manufacturer.
For the ampli¢cation of the mouse myogenin gene, we used the prim-
ers and the conditions previously described [20].
2.7. Gel electrophoresis and analysis of PCR product
Aliquots of the PCR products (15 Wl) were examined by electro-
phoresis in 1.5% agarose gel. Each gel was scanned by a CCD camera
and acquired on the BioImage computerised densitometer. The spe-
ci¢city of the fragments was assessed by restriction analysis.
3. Results and discussion
Cells were exposed to SAM at concentrations ranging from
5 to 200 WM in DM. The cultures were stopped at day 5 and
day 7 after the shift to the SAM-containing medium. The
growth resulted slightly higher than in controls at the lower
concentrations and decreased in a dose-dependent manner
with a three-fold reduction in SAM 200 WM at day 7 (Fig.
1). Up to the concentration of 150 WM SAM, the growth rate
was almost unchanged.
Unlike the growth, myoblast di¡erentiation, evaluated as
percent of fused nuclei, was inhibited by SAM at the concen-
tration of 20 WM (data not shown). The inhibition increased
at higher concentrations. Therefore, SAM seemed to inhibit
di¡erentiation without a¡ecting cell growth at concentrations
below 150 WM.
Given this data, we chose the concentrations of 75 and 150
WM for the following experiments, judging it a good compro-
Fig. 1. Cell growth after 5 or 7 days in culture in di¡erentiation me-
dium.
Fig. 2. Cell di¡erentiation evaluated as CK activity after 5 (upper)
or 7 (lower) days in culture in growth medium, in di¡erentiation
medium and in the presence of SAM.
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mise and borderline conditions between the inhibition of dif-
ferentiation and a normal cell growth. We performed further
di¡erentiation assays comparing the CK activity in cells ex-
posed to 75 and 150 WM of SAM, with control cells cultivated
in GM or DM (Fig. 2).
To assess the SAM e¡ective cellular uptake, we performed
HPLC assays on cell extracts from myoblasts cultivated 48 h
with or without 100 WM SAM in DM, verifying a three-fold
increase in SAM-exposed cells.
Myogenin expression in cells cultured in the presence of 75
and 150 WM SAM for 48 or 72 h, is shown in Fig. 3A. As
already demonstrated [20] the expression at both times was
lower in GM than in DM (lanes 2^5). 75 WM SAM did not
a¡ect the transcription (lane 6) although it a¡ected di¡eren-
tiation, on the contrary transcription seemed slightly higher
than in DM at a later time (lane 5^7). Myogenin expression in
the cells treated with 75 WM SAM is apparently in contrast
with di¡erentiation data. Since it has already been established
that myogenin levels re£ect mRNA synthesis [29], such a con-
trast could either lie in the post-transcriptional regulation or
could be explained by the involvement of other gene(s) which
contribute to the regulation of terminal muscle di¡erentiation.
150 WM SAM, however, sharply repressed the transcription of
myogenin (lanes 8 and 9). For further con¢rmation of these
results, we also investigated the expression of Id3, a negative
regulator of di¡erentiation (Fig. 3B). It was expressed at high
levels in GM (lanes 2 and 3) and poorly expressed in DM
(lanes 4 and 5). SAM did not have an e¡ect on Id3 as it
did on myogenin. Nevertheless the transcription of Id3 in
DM was enhanced (lanes 6^9). These data con¢rmed the in-
volvement of the modulation of gene expression in SAM-
mediated di¡erentiation inhibition. Fig. 3C, shows the plotted
integrated optical density values of signals in previous electro-
phoresis, normalised to Q-actin.
We performed the HpaII/PCR assay to investigate the e¡ect
of SAM on myogenin gene methylation (Fig. 4). The fragment
of 499 bp, ampli¢ed from the 5P-£anking region of the gene,
has a single CCGG site that was fully methylated in GM
(lanes 11 and 12) and in DM after 24 h, but becomes com-
pletely demethylated in DM after 48 h (lanes 13 and 14).
Samples extracted from cells grown in the presence of SAM,
both 75 and 150 WM, show the ampli¢cation of this fragment,
indicating that the investigated site did not undergo demethy-
lation until 48 h (lanes 15^18). The fragment of about 990 bp
visible in lanes relative to EcoRI-digested samples (lanes 2^9)
and in some HpaII-digested samples, was due to the ampli¢-
cation of a fragment recognised by MyoP1 and MyoM7 prim-
ers, but it did not a¡ect the e⁄ciency of the reaction. We
already demonstrated that this CCGG site appears demethyl-
ated in C2C12 cells in DM at 48 h, and that culture condi-
tions resulting in higher myogenin expression and myoblast
di¡erentiation, also result in earlier demethylation [20]. Here
we demonstrate that the repression of di¡erentiation and in-
hibition of myogenin expression, correlate in a delay of meth-
ylated conditions, and that SAM carries out its e¡ects, inhib-
iting the demethylation in a speci¢c manner. These results also
stress the hypothesis that active demethylation acts in balance
with AdoMet-dependent methylation; in fact the inhibitors of
the AdoMet cycle can anticipate the demethylation whereas
SAM can delay it. SAM [20] may be considered as a drug
Fig. 3. Expression of myogenin (A) and Id3 (B) after 48 and 72 h in
culture in GM (lanes 2 and 3), in DM (lanes 4 and 5), and in DM
in the presence of 75 WM SAM (lanes 6 and 7) and 150 WM SAM
(lanes 8 and 9). In lane 10 there is a negative control of the ampli¢-
cation (b) and in lanes 1 and 11 a PX/HaeIII molecular weight
marker (MM) is shown. C: Graphic representation of myogenin
(upper) and Id3 (lower) expression, obtained plotting the optical
density (OD) values of the PCR fragments normalised with the OD
values of Q-actin (not shown).
Fig. 4. Myogenin methylation patterns in C2C12 cells. On the left is
the EcoRI panel, as positive controls, and on the right the HpaII
panel, as methylation-sensitive experiments in GM (lanes 2, 3, 11
and 12), DM (lanes 4, 5, 13 and 14), DM in the presence of 75 WM
SAM (lanes 6, 7, 15 and 16) and DM in presence of 150 WM SAM
(lanes 8, 9, 17 and 18). In lanes 1, 10 and 19 a PX/HaeIII MM is
shown.
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with a well-characterised action, without relevant side-e¡ects,
so that it can be assumed that it does not carry out a wide-
spread methylation, which could result in a toxic behaviour.
The observed e¡ects, increase the hypothetical use of SAM
in the treatment of diseases characterised by abnormal expres-
sion of genes independent by sequence mutation; in particular
we consider the possibility that SAM can also act in modulat-
ing the expression of genes involved in some pathologies.
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